Form 4: Brainstorm Cell Therapeutics Officer Receives Stock Awards

Alla Patlis, Interim CFO & Controller of Brainstorm Cell Therapeutics, reports the acquisition of 65,246 shares of common stock through restricted stock awards.

Summary

• Alla Patlis, Interim Chief Financial Officer & Controller of Brainstorm Cell Therapeutics Inc., reported a transaction on March 11, 2024.
• Patlis acquired 65,246 shares of common stock through restricted stock awards (RSAs).
• The RSAs were granted as part of the Issuer's grant of equity awards in the ordinary course.
• The RSAs will vest in equal yearly installments over two years, on each anniversary of the March 11, 2024 grant date.

Sentiment

Score: 6

Explanation: The document reflects a routine equity grant, which is neutral to slightly positive as it incentivizes management. There are no indications of significant positive or negative events.

Positives

• The grant of restricted stock awards to a key officer aligns their interests with the company's long-term performance.

Future Outlook

The restricted stock awards vest over a two-year period, suggesting a commitment to the company's future performance.

Industry Context

Stock awards are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Stakeholder Impact

• Shareholders may view the stock awards positively as they align management's interests with the company's performance.

Key Dates

Keywords

Brainstorm Cell Therapeutics, BCLI, Alla Patlis, restricted stock awards, Form 4, equity compensation, officer transaction